Patents Represented by Attorney Vertex Pharmaceutical Incorporated
  • Patent number: 8129381
    Abstract: The present invention relates to compounds of formula I: useful as inhibitors of caspases. The present invention also provides pharmaceutically acceptable compositions comprising said compounds, processes for preparing the compounds, and methods of using the compounds and compositions in the treatment of various diseases, conditions, or disorders.
    Type: Grant
    Filed: May 12, 2009
    Date of Patent: March 6, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Ronald Knegtel, Michael Mortimore, John Studley, David Millan
  • Patent number: 8101378
    Abstract: The present invention features vectors that contain a promoter effective for expression in bacterial cells and a promoter effective for expression in insect cells. The dual promoter system allows use of the same vector in both host cell systems so that construction of only a single vector is needed to express a polynucleotide inserted at a downstream cloning site. In preferred embodiments the vector is used to derive a recombinant baculovirus that is used to infect host cells. In particular vectors the promoters are a baculovirus polh promoter and a T7lac promoter. In particular vectors the promoter effective for expression in bacteria is positioned between the promoter effective for expression in insect cells and a cloning site. The invention also features various high throughput screening methods.
    Type: Grant
    Filed: January 19, 2009
    Date of Patent: January 24, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventor: Stephen P. Chambers
  • Patent number: 7960415
    Abstract: The present invention provides a compound of formula I: wherein R1, R2, R3, R4, and R5 are as defined herein. The present invention also provides pharmaceutical compositions and methods using such compositions for treating a caspase-mediated diseases and processes for preparing the compounds of the invention.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: June 14, 2011
    Assignee: Vertex Pharmaceutical Incoporated
    Inventors: Guy Brenchley, Jean-Damien Charrier, Steven Durrant, Ronald Knegtel, Michael Mortimore, John Studley
  • Patent number: 7951820
    Abstract: This invention describes novel triazole compounds of formula IX: wherein Z1 is nitrogen or CR9 and Z2 is nitrogen or CH, provided that at least one of Z1 and Z2 is nitrogen; G is Ring C or Ring D; Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl ring, wherein said Ring C has one or two ortho substituents independently selected from —R1; Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are independently selected from T-R3, or Rx and Ry are taken together with their intervening atoms to form a fused ring; R1, R3, and T are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of GSK-3 and Aurora, for treating diseases such as diabetes, cancer, and Alzheimer's disease.
    Type: Grant
    Filed: July 25, 2006
    Date of Patent: May 31, 2011
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: David Bebbington, Ronald Knegtel, Hayley Binch, Julian M. C. Golec, Pan Li, Jean-Damien Charrier
  • Patent number: 7906650
    Abstract: This invention provides novel compounds, and pharmaceutically acceptable derivatives thereof, that are useful as caspase inhibitors. These compounds have the general formula I: where R1, R2, and R3 are as described herein, Ring A contains zero to two double bonds, each X is independently selected from nitrogen or carbon, at least one X in Ring A is a nitrogen, Ring A is optionally substituted as described, and may be fused to a saturated or unsaturated five to seven membered ring containing zero to three heteroatoms, and provided that when X3 is a carbon, a substituent on X3 is attached by an atom other than nitrogen.
    Type: Grant
    Filed: January 26, 2009
    Date of Patent: March 15, 2011
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Julian M. C. Golec, Paul S. Charifson, Jean-Damien Charrier, Hayley Marie Binch
  • Patent number: 7659283
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.
    Type: Grant
    Filed: February 12, 2007
    Date of Patent: February 9, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Philip Noel Collier, Juan-Miguel Jimenez
  • Patent number: 7622463
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.
    Type: Grant
    Filed: February 13, 2007
    Date of Patent: November 24, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: David Kay, Ronald Knegtel, Jean-Damien Charrier, Heather Twin
  • Patent number: 7605174
    Abstract: The present invention relates to indane derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: June 9, 2006
    Date of Patent: October 20, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Timothy Neubert, Aarti S. Kawatkar, Esther Martinborough, Andreas Termin
  • Patent number: 7598412
    Abstract: The present invention provides compounds of Formula I useful as modulators of ABC transporter activity, or a pharmaceutically acceptable salt thereof, wherein RB, n, B, RC, RD, RE, A, and Z are described generally and in classes and subclasses below. The present invention also provides pharmaceutical compositions, methods and kits associated with Formula I, useful for as modulators, and for the treatments of disease and disease conditions associated with ABC transporter proteins.
    Type: Grant
    Filed: October 8, 2004
    Date of Patent: October 6, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Sara S. Hadida Ruah, Ashvani K. Singh, Mark T. Miller, Matthew Hamilton, Peter D. J. Grootenhuis
  • Patent number: 7592340
    Abstract: The present invention relates to compounds of formula I useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: December 3, 2004
    Date of Patent: September 22, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Guy W. Bernis, John P. Duffy
  • Patent number: 7205327
    Abstract: This invention provides caspase inhibitors having the formula: wherein R1 is CO2H, CH2CO2H, or esters, amides or isosteres thereof; R2 and R3 are each independently selected from hydrogen or an optionally substituted C1–C6 aliphatic group; and R4 and R5 are each independently selected from hydrogen, an optionally substituted C1–C6 aliphatic group, or R4 and R5 taken together with the ring to which they are attached form an optionally substituted bicyclic ring. The caspase inhibitors are useful for treating a number of diseases such as cancer, acute inflammatory and autoimmune disorders, ischemic diseases and certain neurodegenerative disorders.
    Type: Grant
    Filed: November 19, 2001
    Date of Patent: April 17, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: David Kay, Julian M. C. Golec
  • Patent number: 7183307
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: wherein B, R1, n, R3, Q and R4 are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Grant
    Filed: May 3, 2004
    Date of Patent: February 27, 2007
    Assignee: Vertex Pharmaceuticals Incroporated
    Inventors: Michael Robin Hale, James Walter Janetka, Francois Maltais, Qing Tang
  • Patent number: 7179826
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: March 14, 2003
    Date of Patent: February 20, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: David Bebbington, Hayley Binch, Jean-Damien Charrier, Simon Everitt, Julian M. C. Golec, David Kay, Ronald Knegtel, Andrew Miller, Francoise Pierard
  • Patent number: 7169798
    Abstract: The present invention provides compounds of formula I: where R1 is H, CONH2, T(n)-R, or T(n)-Ar2, n may be zero or one, and G, XYZ, and Q are as described below. These compounds are inhibitors of protein kinase, particularly inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Grant
    Filed: February 13, 2004
    Date of Patent: January 30, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jeremy Green, Guy Bemis, Anne-Laure Grillot, Mark Ledeboer, Francesco G. Salituro, Edmund Harrington, Huai Gao, Christopher Baker, Jingrong Cao, Michael Hale
  • Patent number: 7169800
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides processes for preparing the compounds of this invention, pharmaceutically acceptable compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: September 24, 2004
    Date of Patent: January 30, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Alex Aronov, David J. Lauffer, Pan Li, Ronald C. Tomlinson
  • Patent number: 7157476
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: August 20, 2004
    Date of Patent: January 2, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jon H. Come, Jeremy Green, Craig Marhefka, Scott L. Harbeson, Ly Pham
  • Patent number: 7122552
    Abstract: The present invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof. These compounds are inhibitors of protein kinases, particularly inhibitors of JAK and CDK2 mammalian protein kinases. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compounds and compositions in the treatment of various protein kinase mediated disorders.
    Type: Grant
    Filed: May 30, 2003
    Date of Patent: October 17, 2006
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventor: Brian E. Ledford
  • Patent number: 7115746
    Abstract: The present invention relates to processes for the facile synthesis of diaryl amines and analogues thereof. The processes of the present invention produce diaryl amines in high yield and purity. The present invention also relates to intermediates useful in the process of the present invention.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: October 3, 2006
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: John R. Snoonian, Patricia Ann Oliver-Shaffer
  • Patent number: 7115739
    Abstract: This invention describes novel triazole compounds of formula IX: wherein Z1 is nitrogen or CR9 and Z2 is nitrogen or CH, provided that at least one of Z1 and Z2 is nitrogen; G is Ring C or Ring D; Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl ring, wherein said Ring C has one or two ortho substituents independently selected from —R1; Ring D is a 5–7 membered monocyclic ring or 8–10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are independently selected from T-R3, or Rx and Ry are taken together with their intervening atoms to form a fused ring; R1, R3, and T are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of GSK-3 and Aurora, for treating diseases such as diabetes, cancer, and Alzheimer's disease.
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: October 3, 2006
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: David Bebbington, Ronald Knegtel, Hayley Binch, Julian M. C. Golec, Pan Li, Jean-Damien Charier
  • Patent number: 7109357
    Abstract: Disclosed herein is a method for making compounds that are useful as caspase inhibitor prodrugs of formula I: wherein R1 is an optionally substituted group selected from an aliphatic group, aralkyl group, heterocyclylalkyl group or aryl group, and R2 is preferably a P2—P4 moiety of a caspase inhibitor.
    Type: Grant
    Filed: August 28, 2002
    Date of Patent: September 19, 2006
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Marion W. Wannamaker, Cornelia Forster